David Berg

Cardiologist @BrighamWomens | Investigator @TIMIStudyGroup | Crit Care, Shock, Heart Failure, MCS | Desert rat🌵in Boston | Married to @jencrombieMD

[David Berg @ddbergMD]

2 ways to become famous in cardiology:
1) Work hard, contribute something meaningful
2) Hope that your name is serendipitously chosen as the acronym for a large clinical study
#ESCCongress @BrighamFellows

[TIMI Study Group @TIMIStudyGroup]

https://t.co/t6Xbgej0hN @ddbergMD

[Gunnar Henrik Heine @gunnar_heine]

Although DAPA ACT HF-TIMI 68 on SGLT-2 I in AHF is formally a "negative" trial, overall survival and subsequent meta-analytic data confirm the need for early flozination in HF patients
@ddbergMD
https://t.co/WrktXpQ17m

[Gurleen Kaur, MD @Gurleen_Kaur96]

1/ In this #SimPub paper in @CircAHA from #ESCCongress, Berg et al report the findings of the DAPA ACT HF-TIMI 68 trial that investigated the efficacy & safety of in-hospital initiation of dapagliflozin in pts hospitalized for HF

Here's a summary🧵

🔗https://t.co/GqU8R8jobk

[Levent Pay, FESC @leventpy]

🚨 Hot Line 2 at #ESCCongress: DAPA ACT HF results are out!

🔹 No significant reduction in CV death or worsening HF at 2 months
🔹 Overall data still support early SGLT2i use
🔹 Safety profile consistent

@escardio @ddbergMD @TIMIStudyGroup

[Ahmed Bennis MD 🫀 @drbennisahmed]

ESC Congress Madrid 2025

HOT LINE 2
30 August from 08:15 to 09:45

Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial
Optimizing guideline-directed chronic HF therapies during HF hospitalization can improve postdischarge outcomes.

Limited data exist regarding the efficacy and safety of initiating SGLT2is in hospitalized patients with HF.

DAPA ACT HF-TIMI 68 is a cardiovascular outcomes trial evaluating the initiation of dapagliflozin vs placebo in patients hospitalized for the management of acute HF.

The trial has enrolled a high proportion of patients with de novo HF, Black race, and those treated with an angiotensin receptor–neprilysin inhibitor

https://t.co/H8PuRGcRto

[TIMI Study Group @TIMIStudyGroup]

In an analysis of pts w/cardiogenic shock from the @CCCTNetwork registry, PAHR (HR*RAP/MAP) was strongly associated with in-hospital mortality and outperformed traditional hemodynamic metrics @ddbergMD @CurtGinder #AHA24

[TIMI Study Group @TIMIStudyGroup]

In contemporary CICUs, target temperatures for comatose cardiac arrest patients have shifted towards normothermia since publication of the TTM2 Trial. @rwarissmd @ddbergMD @CCCTNetwork #AHA24

[TIMI Study Group @TIMIStudyGroup]

In the first look at the AHA CS Registry, clinician-assigned SCAI staging effectively stratified risk of mortality in patients with CS, supporting clinical translation of SCAI staging to a broad CS population. @ddbergMD @American_Heart #AHA24

[TIMI Study Group @TIMIStudyGroup]

Dr. Robert Ariss presents his oral abstract on Trends In Temperature Control After Cardiac Arrest In Cardiac Intensive Care Units in this @CCCTNetwork analysis, tomorrow at 8am in S101A @rwarissmd @ddbergmd #AHA24

[Gurleen Kaur, MD @Gurleen_Kaur96]

Cardiogenic Shock session at #ACC24

Dr. Morrow @BrighamWomens discusses
🔺complexity of the syndrome
🔺complexity of care
🔺paucity of high quality evidence

Need for team-based approach ⤵️

[Saraschandra Vallabhajosyula, MD MSc @SarasVallabhMD]

Read our review in @CJCJournals led by @EvanWiens and @seanvandiepen on #RenalReplacementTherapy in #CardiogenicShock. Congratulations #JacobJentzer @ElliottMillerMD @ddbergMD @drseanbagshaw. @BrownMedicine @BrownCardiology @BrownUnivHealth. More at - https://t.co/jG7fiNG43q.

[Society Of Critical Care Cardiology @SocietyOfCCC]

Don’t miss a beat in Critical Care Cardiology! 📬 Starting January, our newsletter will be exclusive to registered members of https://t.co/VXZHnrNqqv. Sign up now to stay informed with the latest insights, updates, and breakthroughs – straight to your inbox!

Stay connected and don’t miss out on opportunities to help shape the future of the Society

https://t.co/ZdfkuxEjDa

@AnnGageMD @ElliottMillerMD @JasonKatzMD @BalimSenmanMD @Criticalecho
@SarasVallabhMD @susannaprice @david_enze_wang @LeivaOrly @CardsNYC @SamuelB316 @jason_bartos @PennyRampersad @AlexPapolos @Sam_Brusca @RThachilMD @PabloJ @FH_Verbrugge @HannahSchaubro1 @drdargaray @rafavidalperez @JordiBaneras @krychtiukmd @JFleitmanMD

[CCC Enthusiasts @CCCEnthusiasts]

📣Join us on 11/20 for 2024's final @SocietyOfCCC joint Journal Club, where Dr. @RickyHansra and Dr. @LSpaeth23 will take a deep dive into the management peripartum CMY patients in the CICU🤰. Together, we’ll tackle this challenging and often uncomfortable topic, making it a little less daunting for everyone!!

RSVP today! 👇
🔗https://t.co/UIxTOFja3L

@AnnGageMD @ElliottMillerMD @JasonKatzMD @BalimSenmanMD @Criticalecho
@SarasVallabhMD @susannaprice @ddbergMD @LeivaOrly @CardsNYC @SamuelB316 @jason_bartos @PennyRampersad @AlexPapolos @Sam_Brusca @RThachilMD @PabloJ @FH_Verbrugge @HannahSchaubro1 @drdargaray @rafavidalperez @JordiBaneras @krychtiukmd @JFleitmanMD

[Shashank Sinha, MD, MSc, FACC, FAHA, FHFSA @ShashankSinhaMD]

Phenomenal talk by #DrDavidMorrow on impact of ⁦@CCCTNetwork⁩ on #waronshock #TCT24 ⁦@TCTConference⁩ ⁦@crfheart⁩ ⁦@JasonKatzMD⁩ ⁦@seanvandiepen⁩ ⁦@ddbergMD⁩ ⁦@EBohula⁩ ⁦@SidPatelMD⁩ ⁦@Ajar_Kochar⁩ ⁦@TIMIStudyGroup⁩

[Sean van Diepen @seanvandiepen]

An approach to medical management of mixed shock states guided by hemodynamics and volume assessment.
A full link to the paper: https://t.co/8TPlGlSr3b
5/5

[Critical Care Cardiology Trials Network @CCCTNetwork]

📜CCCTN analysis from @ddberg demonstrates the feasibility & utility of the Shock Academic Research Consortium (SHARC) Consensus Definitions for identifying discrete subtypes of CS - each with distinct clinical profiles and 📊 prognostic implications.

https://t.co/yVEFO7FXGg

[Anju Bhardwaj MD FACC @docbhardwaj]

🔥🔥 ☠️ for phenotypes along preshock -> CS continuum

👉 https://t.co/YpagfPCank

@JACCJournals #JACCHF @CCCTNetwork

🎯 Hypoperfusion +/- hypotension -> ⬆️☠️
🎯 normotensive CS -> distinct CS phenotype
🎯 Identify pre-& early shock to improve #CardiogenicShock outcomes

[Sid M. Patel @SidPatelMD]

The pre-shock ↔️ classic cardiogenic #shock continuum

💡What are the implications of an isolated low CO or isolated hypotension without end-organ injury?
💡 What about normotensive CS?

Now in @JACCJournals #JACCJF from @CCCTNetwork @TIMIStudyGroup

https://t.co/Zq0Jza2uDM

[CCC Enthusiasts @CCCEnthusiasts]

Great addition to your weekend, Dr. @ddbergMD and Dr. @ConnorObrienMD blog on the value of biomarkers in cardiogenic shock is out now. Make sure to check it out!
https://t.co/rLPChizYEO

@AnnGageMD @ElliottMillerMD @JasonKatzMD @BalimSenmanMD @Criticalecho
@SarasVallabhMD @susannaprice @david_enze_wang @LeivaOrly @CardsNYC @SamuelB316 @jason_bartos @PennyRampersad @AlexPapolos @Sam_BruscaDr @RThachilMD @PabloJ @FH_Verbrugge @HannahSchaubro1 @drdargaray @rafavidalperez @JordiBaneras @krychtiukmd @JFleitmanMD @SocietyOfCCC

[TIMI Study Group @TIMIStudyGroup]

Dr. @BrianBergmark joins @marstonMD and @ddbergMD for the final episode of Season 2 of #TIMITalks, to discuss the Bridge-TIMI 73a trial and triglyceride lowering therapies. Listen on all major podcast platforms.